Evidence map›Paper›PMID 41104991›Full record

ReviewImmunotherapy2025

How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy?

Arvind Suresh, Darren Pan, Jodi Lipof, Anupama Kumar, Shagun Arora, Peter Sayre, Jeffrey Wolf, Thomas Martin, Ajai Chari, Alfred Chung

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Arvind SureshDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.
Darren PanDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Jodi LipofDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Anupama KumarDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Shagun AroraDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Peter SayreDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Jeffrey WolfDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Thomas MartinDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Ajai ChariDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.
Alfred ChungDivision of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

B-cell maturation antigen (BCMA) directed chimeric antigen receptor T-cell therapy (CAR-T) has transformed the treatment of relapsed/refractory multiple myeloma (RRMM), yet relapse is still common for most patients. A variety of different salvage treatment strategies have been studied in the last several years to address several resistance mechanisms that lead to relapse after BCMA CAR-T. To date, there are no clear guidelines regarding treatment sequencing strategies for salvage therapy. This review will investigate the current landscape of available salvage therapies and data supporting their use, as well as possible treatment sequencing strategies to maximize clinical outcomes in this difficult-to-treat population.

Indexed as

B-Cell Maturation AntigenImmunotherapy, AdoptiveMultiple MyelomaReceptors, Chimeric AntigenSalvage TherapyT-LymphocytesHumansReceptors, Antigen, T-CellB-Cell Maturation AntigenReceptors, Antigen, T-CellReceptors, Chimeric AntigenBCMAchimeric antigen receptor T-cells (CAR T-cells)GPRC5DMultiple myelomarelapsesalvage therapy

Identifiers

PMID41104991
PMCPMC12582101

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.